The DermatologyNews editorial team covers clinical research, skin conditions, treatments, and developments in dermatology.
From November 15, 2026, iPLEDGE lets prescribers allow home pregnancy tests after the first dose and ends the 19-day lockout. What changes and what stays.
Itchy red or purple patches on toes and fingers after cold, damp weather: how chilblains differ from Raynaud's, when to get checked and what trials show.
Icotrokinra (Icotyde) is a once-daily tablet that blocks the IL-23 receptor. What the phase 3 trials, the US label and the labels of other psoriasis pills show.
Inverse psoriasis forms smooth red plaques in skin folds. What the evidence shows for steroid, nonsteroidal and systemic treatment, and which rashes look alike.
Learn how to check a dermatology paper in PubMed for corrections, expressions of concern and retractions, and how to read each notice accurately.
Injection-site reactions, conjunctivitis and facial redness: what the Dupixent label and phase 3 trials show, and which symptoms the label says to report.
The FDA added knee skin laxity to Ulthera's US indications in May 2026. Read what changed, what the small studies show, and questions to ask a clinician.
Which acne treatments carry strong recommendations for adolescents in the 2024 American Academy of Dermatology guideline, what the trials behind them found, and where the evidence is thin.
The FDA added bemotrizinol to the OTC sunscreen monograph in June 2026. What the order allows, what absorption and stability data show, and what is unknown.
Actinic keratosis is a precursor to squamous cell carcinoma. What the progression data show, and how fluorouracil, imiquimod, and photodynamic therapy compared in a head-to-head trial.
Standard microfocused ultrasound protocols are single-session. What the evidence says about repeating treatment, combining devices in one visit, and why patient and investigator ratings diverge.
The rough bumps on upper arms and thighs are common and harmless. What trials show about keratolytics, lasers, and intense pulsed light, and why recurrence is the expected outcome.
An emerging dermatophyte species is poorly responsive to terbinafine and cannot be identified without molecular testing. What the resistance data show and what they change in practice.
Falling humidity and temperature measurably weaken the skin barrier. What changes in autumn, what moisturizers do, and when dryness needs a doctor.
Hair shedding follows an annual rhythm that peaks in early autumn. What trichogram and search data show, how much is normal, and when to seek care.
Why seborrheic dermatitis flares as weather cools, plus trial evidence on roflumilast foam, the first FDA-approved PDE4 inhibitor for the disease.
Baricitinib, ritlecitinib, and deuruxolitinib are FDA approved for severe alopecia areata. Compare age limits, trials, boxed warnings, and evidence gaps.
Clascoterone is an FDA-approved topical androgen receptor inhibitor for acne. See the phase 3 results, limits, adverse effects, and unanswered comparisons.
Delgocitinib cream is FDA approved for some adults with chronic hand eczema. Review the phase 3 results, label limits, safety warnings, and evidence gaps.
The FDA received reports of serious complications with certain RF microneedling uses in 2025. Learn what was reported, remains unknown, and how needling differs.
Lebrikizumab and nemolizumab target different atopic dermatitis pathways. Compare their FDA labels, phase 3 designs, safety limits, and evidence gaps.
Ruxolitinib cream can improve facial repigmentation in some people with nonsegmental vitiligo. Review the FDA label, trial outcomes, timeline, and risks.
Hypochlorous acid face spray is popular, but human evidence mainly comes from wound care. See what HOCl may do, what remains unproven, and safety limits.
Mechanism, efficacy data, downtime, and the post-inflammatory hyperpigmentation risk that dominates ablative fractional CO2 resurfacing for atrophic acne scars, with a focus on darker and Asian skin.
How microfocused ultrasound, monopolar radiofrequency, and RF microneedling differ for skin tightening, and how clinicians choose the right energy-based option.
Erythema nodosum causes tender red nodules on the shins and often signals an underlying trigger. What causes it, how it is diagnosed, and how it is treated.
Why lasers and energy-based devices can trigger post-inflammatory hyperpigmentation, who is most at risk, and what the evidence supports to prevent and treat it.
What solar lentigines are, how they differ from other pigmented spots, and what the evidence supports for lasers, IPL, cryotherapy, peels, and topical agents.
What randomized trials and meta-analyses show about tranexamic acid for melasma, including efficacy by route (oral, topical, injected), safety, and who should avoid it.
How clinicians tell melasma, post-inflammatory hyperpigmentation, and solar lentigines apart, why it changes treatment and prognosis, and the evidence-based options for each.
What the evidence supports for male androgenetic alopecia: minoxidil, finasteride and dutasteride, adjunct options, and realistic expectations on results and risks.
A phenotype-based guide to rosacea: how flushing, persistent redness, papules and pustules, visible vessels, and eye involvement are treated, and why trigger control matters.
How topical retinoids work, how prescription tretinoin compares with retinaldehyde, retinol, and adapalene, and how to choose a tolerable option for aging or acne-prone skin.
How clinicians classify atrophic acne scars (ice-pick, boxcar, rolling) and what the evidence supports for subcision, fractional lasers, microneedling RF, and fillers.
What the evidence supports for treating common and plantar warts, why salicylic acid and cryotherapy are first-line, and when persistent warts need a different approach.
The World Federation for Ultrasound in Medicine and Biology (WFUMB) released 24 consensus recommendations standardizing dermatologic ultrasound for aesthetic procedures: what changed and what it means for practice.
Do exosome skin treatments work? Reviews find encouraging short-term signals, but mostly non-randomized studies and unresolved long-term safety gaps remain.
How topical and low-dose oral minoxidil fit into female pattern hair loss treatment, with evidence on diagnosis, combination therapy, adherence, and adverse effects.
After rapid weight loss on GLP-1 drugs, loose skin on the abdomen, arms, and thighs is common. What the evidence says about energy-based tightening, biostimulators, timing, and when surgery is the realistic option.
Hair loss reported with semaglutide and tirzepatide: what the evidence shows about telogen effluvium, androgenetic alopecia, diagnosis, and recovery.
What 41 studies show about RF microneedling efficacy, how devices differ, and why the FDA's 2025 serious-complication reports limit broad safety claims.
Why adult-onset acne in women is often hormonally driven, how it differs from adolescent acne, and what the evidence supports for combined oral contraceptives, spironolactone, and topical therapy.
Why GLP-1 receptor agonists cause facial volume loss, severity predictors, and the published multimodal restoration approaches in 2026.
Why visible light, not just UV, drives melasma and post-inflammatory pigmentation, and what tinted iron oxide sunscreens add to a summer skin care routine in 2026.
What polynucleotide injectables do, what the systematic review data shows, how they compare with HA boosters, adverse events, and patient selection.
Mechanism of collagen induction, expected timeline, reconstitution evidence, recognized complications, and patient selection for PLLA.
Mechanism, timeline, comparator data vs MFU-V, adverse events, and patient selection for monopolar radiofrequency facial tightening.
MFU-V means microfocused ultrasound with visualization in aesthetic medicine. Review skin-tightening results, safety, timelines, and patient selection.
Evidence for FDA-approved hydroquinone, tretinoin and fluocinolone cream for melasma: efficacy versus monotherapy, adverse effects and adjunctive options.
What patients should ask and clinicians should disclose before MFU-V, radiofrequency or combination skin tightening: a checklist and red flags.